ResearcherEast China Normal UniversityActive in the last 2 years
Yihua Chen
Matched on ORCID iD 0000-0003-1733-7980; OpenAlex author ID A5047949320. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 0, last author 3)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 11
2011: 1 paper · 2012: none · 2013: none · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: 1 paper · 2020: none · 2021: none · 2022: 2 papers · 2023: 1 paper · 2024: 1 paper
Papers 6
- Discovery of the Highly Selective and Potent STAT3 Inhibitor for Pancreatic Cancer Treatment. Co-author DOI 10.1021/acscentsci.3c01440↗
- Selectively Targeting STAT3 Using a Small Molecule Inhibitor is a Potential Therapeutic Strategy for Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-22-0997↗
- Discovery of a Highly Potent and Orally Bioavailable STAT3 Dual Phosphorylation Inhibitor for Pancreatic Cancer Treatment. Last author DOI 10.1021/acs.jmedchem.2c01554↗
- Discovery of 1,5-diaryl-1,2,4-triazole derivatives as myoferlin inhibitors and their antitumor effects in pancreatic cancer. Last author DOI 10.4155/fmc-2022-0168↗
- Modification and Biological Evaluation of a Series of 1,5-Diaryl-1,2,4-triazole Compounds as Novel Agents against Pancreatic Cancer Metastasis through Targetin… Last author DOI 10.1021/acs.jmedchem.9b00059↗
- Hispidulin, a small flavonoid molecule, suppresses the angiogenesis and growth of human pancreatic cancer by targeting vascular endothelial growth factor recep… Co-author DOI 10.1111/j.1349-7006.2010.01778.x↗
Closest collaborators
The 11 strongest of 11 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Zhengfang Yi · 6 shared papers, 2011–2024 · strength 0.75
- Paper Discovery of the Highly Selective and Potent STAT3 Inhibitor for Pancreatic Cancer Treatment. DOI 10.1021/acscentsci.3c01440↗
- Paper Selectively Targeting STAT3 Using a Small Molecule Inhibitor is a Potential Therapeutic Strategy for Pancreatic Cancer. DOI 10.1158/1078-0432.ccr-22-0997↗
- Paper Discovery of 1,5-diaryl-1,2,4-triazole derivatives as myoferlin inhibitors and their antitumor effects in pancreatic ca… DOI 10.4155/fmc-2022-0168↗
- Mingyao Liu · 5 shared papers, 2011–2024 · strength 0.59
- Paper Discovery of the Highly Selective and Potent STAT3 Inhibitor for Pancreatic Cancer Treatment. DOI 10.1021/acscentsci.3c01440↗
- Paper Selectively Targeting STAT3 Using a Small Molecule Inhibitor is a Potential Therapeutic Strategy for Pancreatic Cancer. DOI 10.1158/1078-0432.ccr-22-0997↗
- Paper Discovery of a Highly Potent and Orally Bioavailable STAT3 Dual Phosphorylation Inhibitor for Pancreatic Cancer Treatme… DOI 10.1021/acs.jmedchem.2c01554↗
- Peng He · 3 shared papers, 2022–2024 · strength 0.48
- Paper Discovery of the Highly Selective and Potent STAT3 Inhibitor for Pancreatic Cancer Treatment. DOI 10.1021/acscentsci.3c01440↗
- Paper Discovery of 1,5-diaryl-1,2,4-triazole derivatives as myoferlin inhibitors and their antitumor effects in pancreatic ca… DOI 10.4155/fmc-2022-0168↗
- Paper Discovery of a Highly Potent and Orally Bioavailable STAT3 Dual Phosphorylation Inhibitor for Pancreatic Cancer Treatme… DOI 10.1021/acs.jmedchem.2c01554↗
- Zhenliang Sun · 2 shared papers, 2023–2024 · strength 0.34
- Chen Huang · 2 shared papers, 2023–2024 · strength 0.34
- Yunqi Li · 2 shared papers, 2019–2022 · strength 0.24
- Paper Discovery of 1,5-diaryl-1,2,4-triazole derivatives as myoferlin inhibitors and their antitumor effects in pancreatic ca… DOI 10.4155/fmc-2022-0168↗
- Paper Modification and Biological Evaluation of a Series of 1,5-Diaryl-1,2,4-triazole Compounds as Novel Agents against Pancr… DOI 10.1021/acs.jmedchem.9b00059↗
- Haijun Gu · 1 shared paper, 2022 · strength 0.16
- Xin Wang · 1 shared paper, 2019 · strength 0.08
- Lijun He · 1 shared paper, 2011 · strength 0.03
- Xiufeng Pang · 1 shared paper, 2011 · strength 0.03
- Jieqiong Wang · 1 shared paper, 2011 · strength 0.03
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.